Solazyme Receives FDA GRAS No Questions Letter for High Oleic Algae Oil
25 February 2015 - 2:50PM
Business Wire
Solazyme, Inc. (NASDAQ:SZYM), a renewable oil and ingredients
company, is pleased to announce that the US Food and Drug
Administration (FDA) has issued a favorable response to Solazyme’s
notification which concludes that high-oleic algae oil is Generally
Recognized as Safe (GRAS) as an ingredient in food products under
the intended conditions of use.
This No Questions letter will further pave the way for
mainstream adoption of superior quality oleic algae oil with
unprecedented functional, performance and nutritional benefits,
enabling the creation of new products that meet consumer demand for
healthy, sustainable ingredients.
Solazyme’s portfolio of high oleic algae oils are unique in that
they can offer an unprecedented amount of healthy monounsaturated
fat (omega-9s), and 0g trans fat with exceptional stability and low
levels of saturated fat. They have a very light color and neutral
flavor allowing the flavor of foods to come through in recipes.
Solazyme’s High Stability High Oleic algae oil received the
prestigious 2014 Innovation Award from the Institute of Food
Technologists.
“We’re committed to delivering innovative ingredients that are
better for both people and the planet. Our algae oils offer more
favorable fat profiles than olive oil, and higher smoke points than
canola, helping customers respond to the growing demand for great
tasting and nutritious food,” said Mark Brooks, SVP, Solazyme Food
Ingredients.
Solazyme has also received FDA No Questions letters for the
whole food ingredient products currently offered within the
AlgaVia™ portfolio, including Whole Algal Protein and Whole Algal
Flour.
Whole Algal Protein is a vegan-friendly, gluten-free product
that contains a rich collection of protein with fiber, lipids and
micronutrients such as lutein and zeaxanthin. With a protein that
is protected by a natural cell wall, this ingredient enables
fortification in challenging applications such as low pH beverages,
dressings and crackers.
Whole Algal Flour is a trans-fat- and cholesterol-free lipid
powder that enables the creation of healthier products with
satisfying taste and texture. This new fat source enables the
reduction or replacement of dairy fats, oil and egg yolks.
About Solazyme, Inc.
Solazyme, Inc. (Nasdaq:SZYM) is a leading microalgae
innovator that delivers first-of-a-kind, high-performance oils and
ingredients that are better for people and better for the
planet. Starting with microalgae, the world’s original oil
producer, Solazyme creates new, sustainable, high-performance
products. These include renewable oils and powerhouse ingredients
that serve as the foundation for healthier foods; better home,
personal care and industrial products; and more sustainable
fuels. Headquartered in South San
Francisco, Solazyme’s mission is to solve some of the world’s
biggest problems with one of its smallest and most ancient life
forms: microalgae.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 about Solazyme, including statements that involve risks and
uncertainties concerning: its commercialization and production
plans; meeting commercialization and technology targets; market
acceptance of its products; and Solazyme’s ability to maintain its
relationships with its partners. When used in this press release,
the words “will”, “can”, “anticipate”, “intends” and other similar
expressions and any other statements that are not historical facts
are intended to identify those assertions as forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Any such statement may be influenced by a
variety of factors, many of which are beyond the control of
Solazyme, that could cause actual outcomes and results to be
materially different from those projected, described, expressed or
implied in this press release due to a number of risks and
uncertainties. Potential risks and uncertainties include, among
others: Solazyme’s limited operating history; its limited history
in commercializing products; implementation risk in deploying new
technologies; its limited experience in constructing, ramping up
and operating commercial manufacturing facilities; its ability to
sell its products at a profit; delays related to start-up and
ramp-up of production facilities; its ability to manage operational
costs at production facilities; its ability to enter into and
maintain strategic collaborations; successful product trials by its
customers and market acceptance of its products by end-users; its
ability to obtain requisite regulatory approvals; and its access,
on favorable terms, to any required financing. Accordingly, no
assurances can be given that any of the events anticipated by the
forward-looking statements will transpire or occur, or if any of
them do so, what impact they will have on the results of operations
or financial condition of Solazyme.
In addition, please refer to the documents that Solazyme, Inc.
files with the Securities and Exchange Commission, including its
Quarterly Report on Form 10-Q, as updated from time to time, for a
discussion of these and other risks. You are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date of this press release. Solazyme is not under any duty
to update any of the information in this press release.
Solazyme, Inc.Genet Garamendi, 650-780-4777VP of
CommunicationsPress@solazyme.com